Baird lowered the firm’s price target on Bright Minds (DRUG) to $126 from $142 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results as the company gears up for epilepsy and PWS trial initiations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG:
- Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss
- Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline
- Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline
- Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
- Bright Minds 1.945M share Secondary priced at $90.00